Gaucher disease ascertained through a Parkinson's center: Imaging and clinical characterization

Movement Disorders

Volumn 25, Issue 10, 2010, Pages 1364-1372

  Saunders Pullman, Rachel ^a,b   Hagenah, Johann ^c   Dhawan, Vijay ^d   Stanley, Kaili ^a   Pastores, Gregory ^e   Sathe, Swati ^e   Tagliati, Michele ^f   Condefer, Kelly ^a   Palmese, Christina ^a   Brüggemann, Norbert ^c   Klein, Christine ^c   Roe, A M ^b   Kornreich, Ruth ^f   Ozelius, Laurie ^f   Bressman, Susan ^a,b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF LÜBECK   (Germany)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Functional imaging; Gaucher disease; Glucocerebrosidase mutations transcranial sonography; Olfaction; Parkinson's disease

Indexed keywords

6 FLUORODOPA F 18; FLUORODEOXYGLUCOSE; GLUCOSYLCERAMIDASE;

ADULT; AGED; ARTICLE; BRAIN REGION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIFFUSE LEWY BODY DISEASE; ECHOGRAPHY; FEMALE; GAUCHER DISEASE; GENE MUTATION; GENETIC SCREENING; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HYPERMETABOLISM; JEW; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SMELLING; SMELLING DISORDER; SUBSTANTIA NIGRA;

ADULT; AGED; DIHYDROXYPHENYLALANINE; FEMALE; FLUORODEOXYGLUCOSE F18; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEUROPSYCHOLOGICAL TESTS; OLFACTION DISORDERS; PARKINSON DISEASE; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 77954972471     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23046     Document Type: Article

References (55)

1. Rogaeva E, Hardy J. Gaucher and Parkinson diseases: unexpectedly related. Neurology 2008;70:2272-2273.
2. Gan-Or Z, Giladi N, Rozovski U, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008;70:2277-2283.
3. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008;65: 1353-1357.
4. Mckeran RO, Bradbury P, Taylor D, Stern G. Neurological involvement in type 1 (adult) Gaucher's disease. J Neurol Neurosurg Psychiatry 1985;48:172-175.
5. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996;89:691-694. (Pubitemid 26319021)
6. Cherin P, Sedel F, Mignot C, et al. Neurological manifestations of type 1 Gaucher's disease: is a revision of disease classification needed? Rev Neurol (Paris) 2006;162:1076-1083.
7. Clark LN, Ross BM, Wang Y, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007;69:1270-1277. (Pubitemid 47429028)
8. Machaczka M, Rucinska M, Skotnicki AB, Jurczak W. Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am J Hematol 1999;61:216-217.
9. Tayebi N, Callahan M, Madike V, et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001;73:313-321.
10. Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 2003;79:104-109.
11. Wong K, Sidransky E, Verma A, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004;82:192-207.
12. Lwin A, Orvisky E, Goker-Alpan O, Lamarca ME, Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004;81:70-73.
13. Goker-Alpan O, Schiffmann R, Lamarca ME, Nussbaum RL, Mcinerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet 2004;41:937-940.
14. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351:1972-1977.
15. Clark LN, Nicolai A, Afridi S, et al. Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov Disord 2005;20:100-103.
16. Sato C, Morgan A, Lang AE, et al. Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord 2005;20:367-370.
17. Nichols WC, Pankratz N, Marek DK, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009;72:310-316.
18. Eblan MJ, Scholz S, Stubblefield B, et al. Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with Parkinsonism. Neurosci Lett 2006;404:163-165.
19. Ziegler SG, Eblan MJ, Gutti U, et al. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 2007;91:195-200.
20. Tan EK, Tong J, Fook-Chong S, et al. Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol 2007;64:1056-1058.
21. Bras J, Paisan-Ruiz C, Guerreiro R, et al. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging 2007.
22. Toft M, Pielsticker L, Ross OA, Aasly JO, Farrer MJ. Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 2006;66:415-417.
23. De Marco EV, Annesi G, Tarantino P, et al. Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov Disord 2008;23:460-463.
24. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009.
25. Clark LN, Kartsaklis LA, Wolf Gilbert R, et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009;66:578-583.
26. Pankratz N, Nichols WC, Uniacke SK, et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without Parkin mutations. Am J Hum Genet 2002;71:124-135.
27. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354:424-425.
28. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
29. Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Caine DB, editors. Recent developments in Parkinson's disease. New Jersey: Macmillan Healthcare Information; 1987. p 153-163.
30. Wechsler D. Wechsler adult intelligence scale, Third ed. Texas: The Psychological Corporation; 1997.
31. Heaton RK, Miller SW, Taylor MJ, Grant I. Revised comprehensive norms for an expanded halstead-reitan battery: demographically adjusted neuropsychological norms for African American and Caucasian adults. Professional manual. Florida: Psychological Assessment Resources; 2004.
32. Reitan RM, Wolfson D. The Halsted- Reitan neuropsychological test battery, Arizona: Neuropsychology Press; 1985.
33. Wechsler D. Wechsler test of adult reading, Texas: The Psychological Corporation; 1997.
34. Barona A, Reynolds C, Chastain R. A demographically based index of premorbid intelligence for the WAIS-R. J Consulting Clin Psychology 1984;52:885-887.
35. Kaplan E, Goodglass H, Weintraub S. Boston naming test, Second ed. Texas: Pro-Ed Inc.; 2001.
36. Woodard JL, Benedict RH, Salthouse TA, Toth JP, Zgaljardic DJ, Hancock HE. Normative data for equivalent, parallel forms of the judgment of line orientation test. J Clin Exp Neuropsychol 1998;20:457-462.
37. Wechsler D. Wechler memory scale, Third ed. Texas: The Psychological Corporation; 1997.
38. Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995-2004.
39. Dhawan V, Ma Y, Pillai V, et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med 2002;43:1324-1330.
40. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania smell identification test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984;32:489-502.
41. Hagenah JM, Konig IR, Becker B, et al. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol 2007;254:1407-1413.
42. Hagenah JM, Becker B, Bruggemann N, et al. Transcranial sonography findings in a large family with homozygous and heterozygous PINK1 mutations. J Neurol Neurosurg Psychiatry 2008; 79:1071-1074.
43. Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry 2005;76: 423-425.
44. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812-819.
45. Walter U, Dressler D, Wolters A, Probst T, Grossmann A, Benecke R. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 2004;63:504-509.
46. Zecca L, Berg D, Arzberger T, et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 2005;20:1278-1285.
47. Korkotian E, Schwarz A, Pelled D, Schwarzmann G, Segal M, Futerman AH. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J Biol Chem 1999; 274:21673-21678.
48. Walter U, Dressler D, Wolters A, Wittstock M, Greim B, Benecke R. Sonographic discrimination of dementia with Lewy bodies and Parkinson's disease with dementia. J Neurol 2006; 253:448-454.
49. Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
50. Kono S, Shirakawa K, Ouchi Y, et al. Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier. J Neurol Sci 2007;252: 181-184.
51. Goker-Alpan O, Giasson BI, Eblan MJ, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006;67:908-910.
52. Mata IF, Cosentino C, Marca V, et al. LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. Parkinsonism Relat Disord 2008.
53. Zimran A, Neudorfer O, Elstein D. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2005; 352:728-731.
54. Hughes DA, Ginsberg L, Baker R, et al. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat. Parkinsonism Relat Disord 2007;13:365-368.
55. Goker-Alpan O, Sidransky E. Treating patients with Gaucher disease and parkinsonism: misrepresentation in a title. Parkinsonism Relat Disord 2008;14:81.